問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃柏豪

Recruiting

List

34Cases

2013-04-01 - 2022-12-05

Phase IV

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, AutoantibodyPositive Systemic Lupus Erythematosus Receiving Belimumab

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BENLYSTA (Belimumab)

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

黃春明
China Medical University Hospital

2019-09-01 - 2022-12-17

Phase II

An adaptive Phase 2 randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of multiple LOU064 doses in patients with moderate to severe Sjögren’s Syndrome (LOUiSSe)

  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    LOU064

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

藍忠亮
China Medical University Hospital

2020-08-01 - 2023-06-26

Phase III

A two-year, phase III randomized, double-blind, parallel-group, placebocontrolled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis

  • Condition/Disease

    active lupus nephritis

  • Test Drug

    AIN457

Participate Sites
4Sites

Recruiting4Sites

2021-03-01 - 2024-12-10

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB